Orit Karni-Schmidt, Ph.D. - Publications

Affiliations: 
Columbia University, New York, NY 
Area:
p53 tumour suppressor protein

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Beckerman R, Yoh K, Mattia-Sansobrino M, Zupnick A, Laptenko O, Karni-Schmidt O, Ahn J, Byeon IJ, Keezer S, Prives C. Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. Cell Cycle (Georgetown, Tex.). 1-14. PMID 27210019 DOI: 10.1080/15384101.2016.1170270  0.717
2016 Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. Annual Review of Pathology. PMID 27022975 DOI: 10.1146/Annurev-Pathol-012414-040349  0.727
2015 Gaya JM, López-Martínez JM, Karni-Schmidt O, Bonal DM, Algaba F, Palou J, Villavicencio H, Benson MC, Cordon-Cardo C, Castillo-Martin M. ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer. The Journal of Urology. 193: 1144-50. PMID 25444981 DOI: 10.1016/J.Juro.2014.10.098  0.358
2012 Gaya JM, Castillo-Martin M, Lopez-Martinez JM, Karni-Schmidt O, Gladoun N, Algaba F, Palou J, Villavicencio H, Benson MC, Cordon-Cardo C. 385 DELTAN P63 (ΔNP63) EXPRESSION AS A PROGNOSTIC FACTOR OF PROGRESSION IN CLINICAL HGT1 BLADDER CANCER Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.449  0.436
2011 Karni-Schmidt O, Castillo-Martin M, Shen TH, HuaiShen T, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. The American Journal of Pathology. 178: 1350-60. PMID 21356385 DOI: 10.1016/J.Ajpath.2010.11.061  0.689
2010 Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C. Molecular pathways of urothelial development and bladder tumorigenesis. Urologic Oncology. 28: 401-8. PMID 20610278 DOI: 10.1016/J.Urolonc.2009.04.019  0.438
2008 Karni-Schmidt O, Zupnick A, Castillo M, Ahmed A, Matos T, Bouvet P, Cordon-Cardo C, Prives C. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. Journal of Cell Science. 121: 4098-105. PMID 19033390 DOI: 10.1242/Jcs.030098  0.785
2007 Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, Mattia M, Beckerman R, Bouvet P, Sheetz M, Fersht A, Prives C. Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene. 26: 3878-91. PMID 17237827 DOI: 10.1038/Sj.Onc.1210162  0.527
2003 Poyurovsky MV, Jacq X, Ma C, Karni-Schmidt O, Parker PJ, Chalfie M, Manley JL, Prives C. Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Molecular Cell. 12: 875-87. PMID 14580339 DOI: 10.1016/S1097-2765(03)00400-3  0.746
2001 Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Molecular and Cellular Biology. 21: 1066-76. PMID 11158294 DOI: 10.1128/Mcb.21.4.1066-1076.2001  0.785
Show low-probability matches.